Opicapone as an adjunct to levodopa in patients with Parkinson's disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial -

Opicapone as an adjunct to levodopa in patients with Parkinson's disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial
Information type: Randomised controlled trials
Source: The Lancet Neurology
Specialities: Neurological disorders
Summary
In this RCT of patients with Parkinson’s Disease on levodopa therapy with end of dose motor fluctuations (n=590) opicapone 50mg once daily was superior to placebo in mean change in time in the “off-state” (mean difference in change from baseline −60.8 min p=0.0015)
UKMi comment
In this RCT opicapone, (a peripherally selective inhibitor of catechol-O-methyltransferase) given at a dose of 50mg once daily was also non-inferior to entacapone 200mg given with each dose of levodopa. Treatment emergent adverse effects were reported in 50% of patients on placebo vs 57% with entacapone and 54% for opicapone 50mg. A related commentary highlights that availability of this new treatment may significantly affect clinical practice due to the favourable risk-benefit ratio for opicapone and its convenient once daily administration
Related links: Lancet Neurology Commentary